Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
Antibodies, Monoclonal, Humanized
Carcinoma, Squamous Cell
In a cohort of patients with resected lung cancers at high risk of hemoptysis, including those with SQCLC, treatment with adjuvant bevacizumab did not result in hemoptysis of any grade.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency